BACKGROUND:Cisplatin-induced ototoxicity shows high interindividual variability and is often accompanied by transient or permanent tinnitus. It is not possible to identify the susceptible individuals before commencement of the treatment. We conducted a prospective, randomized and observational study in a tertiary care centre and evaluated the effects of different doses of cisplatin on hearing. MATERIALS AND METHODS:Fifty-seven patients scheduled forcisplatin-based chemotherapy were included in the study. All patients were divided into three groups depending on the dose of cisplatin infused in 3 weeks. RESULTS: The subjective hearing loss was found in seven patients, while six patients had tinnitus during the chemotherapy. The hearing loss was sensorineural, dose dependent, symmetrical, bilateral and irreversible. Higher frequencies were first to be affected in cisplatin chemotherapy. CONCLUSION: As use of high-frequency audiometry is still limited in research work only, we need a strict protocol of adding high-frequency audiometry in the cisplatin-based chemotherapy regimen.
RCT Entities:
BACKGROUND:Cisplatin-induced ototoxicity shows high interindividual variability and is often accompanied by transient or permanent tinnitus. It is not possible to identify the susceptible individuals before commencement of the treatment. We conducted a prospective, randomized and observational study in a tertiary care centre and evaluated the effects of different doses of cisplatin on hearing. MATERIALS AND METHODS: Fifty-seven patients scheduled for cisplatin-based chemotherapy were included in the study. All patients were divided into three groups depending on the dose of cisplatin infused in 3 weeks. RESULTS: The subjective hearing loss was found in seven patients, while six patients had tinnitus during the chemotherapy. The hearing loss was sensorineural, dose dependent, symmetrical, bilateral and irreversible. Higher frequencies were first to be affected in cisplatin chemotherapy. CONCLUSION: As use of high-frequency audiometry is still limited in research work only, we need a strict protocol of adding high-frequency audiometry in the cisplatin-based chemotherapy regimen.
Authors: Hyejeong Hong; David W Dowdy; Kelly E Dooley; Howard W Francis; Chakra Budhathoki; Hae-Ra Han; Jason E Farley Journal: Am J Audiol Date: 2020-04-22 Impact factor: 1.493
Authors: Marilyn F Dille; Debra Wilmington; Garnett P McMillan; Wendy Helt; Stephen A Fausti; Dawn Konrad-Martin Journal: J Am Acad Audiol Date: 2012 Jul-Aug Impact factor: 1.664
Authors: Marilyn F Dille; Dawn Konrad-Martin; Frederick Gallun; Wendy J Helt; Jane S Gordon; Kelly M Reavis; Gene W Bratt; Stephen A Fausti Journal: J Am Acad Audiol Date: 2010-06 Impact factor: 1.664
Authors: Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille Journal: Int J Audiol Date: 2017-11-20 Impact factor: 2.117